|
|
| Alternative Name : |
AAT3, FAA3, MFS2, RIIC, LDS1B, LDS2B, TAAD2, TGFR-2, TGFbeta-RII, TGFBR-2, TGF-beta receptor type-2, Transforming growth factor-beta receptor type II, TGF-beta receptor type II, TGF-beta type II receptor, TbetaR-II, TGFBR2. |
| Amount : |
10 µg |
Source : Escherichia Coli.
TGFBR2 Human Recombinant produced in E.Coli is a single, non-glycosylated, polypeptide chain encoding 133 amino acids (27-159 a.a.), the extracellular domain of TGFBR2, having a molecular mass of 15.1 kDa.TGFBR2 is purified by proprietary chromatographic techniques
TGFBR2 is part of the Ser/Thr protein kinase family and the TGFB receptor subfamily. TGFBR2 is a transmembrane protein that has a protein kinase domain, forms a heterodimeric complex with another receptor protein, and binds TGF-beta. This receptor/ligand complex phosphorylates proteins, which then enter the nucleus and regulate the transcription of a subset of genes related to cell proliferation. Mutations in TGFBR2 gene have been associated with Marfan syndrome, Loeys-Deitz Aortic Aneurysm Syndrome, and the development of various types of tumors. TGFBR2 expression is increased in oral squamous cell carcinoma cells. TGFBR2 attenuates the biological activities of TGF-beta in colorectal cancer. TGFBR2 expression is decreased by IL-1beta while inducing Sp3 via NFkappaB. TGFB2 and TGFBR2 are involved in the antiestrogenic activity of tamoxifen metabolites in breast cancer.
It is recommended to reconstitute the lyophilized TGFBR2 in sterile 18MΩ-cm H2O not less than 100µg/ml, which can then be further diluted to other aqueous solutions. In ELISA assay, concentrations 0.5-1µg/ml can be used for TGF-beta measurements
